This post was originally published on this site
Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, new research suggests.
Headline
Zepbound outperforms Ozempic and Wegovy in head-to-head weight loss study
Back To Top